Eisai's US perampanel resubmission accepted for review
This article was originally published in Scrip
The US FDA has formally accepted for review Eisai's resubmission of a new drug application for its novel epilepsy product perampanel, setting the Prescription Drug User Fee Act target date for 22 October.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.